| Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer MJ Watt, AK Clark, LA Selth, VR Haynes, N Lister, R Rebello, LH Porter, ... Science translational medicine 11 (478), eaau5758, 2019 | 285 | 2019 |
| AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965 TA Dite, CG Langendorf, A Hoque, S Galic, RJ Rebello, AJ Ovens, ... Journal of Biological Chemistry 293 (23), 8874-8885, 2018 | 126 | 2018 |
| Therapeutic approaches targeting MYC-driven prostate cancer RJ Rebello, RB Pearson, RD Hannan, L Furic Genes 8 (2), 71, 2017 | 107 | 2017 |
| Patient-derived models of abiraterone-and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy MG Lawrence, D Obinata, S Sandhu, LA Selth, SQ Wong, LH Porter, ... European urology 74 (5), 562-572, 2018 | 106 | 2018 |
| Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth HB Pearson, J Li, VS Meniel, CM Fennell, P Waring, KG Montgomery, ... Cancer discovery 8 (6), 764-779, 2018 | 103 | 2018 |
| Proteomic profiling of human prostate Cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the tumor microenvironment*[S] EV Nguyen, BA Pereira, MG Lawrence, X Ma, RJ Rebello, H Chan, ... Molecular & Cellular Proteomics 18 (7), 1410-1427, 2019 | 86 | 2019 |
| mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans VG Puelles, JW Van Der Wolde, N Wanner, MW Scheppach, ... JCI insight 4 (18), 2019 | 85 | 2019 |
| The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer RJ Rebello, E Kusnadi, DP Cameron, HB Pearson, A Lesmana, JR Devlin, ... Clinical Cancer Research 22 (22), 5539-5552, 2016 | 83 | 2016 |
| The influence of BRCA2 mutation on localized prostate cancer RA Taylor, M Fraser, RJ Rebello, PC Boutros, DG Murphy, RG Bristow, ... Nature Reviews Urology 16 (5), 281-290, 2019 | 74 | 2019 |
| From sphingosine kinase to dihydroceramide desaturase: a structure–activity relationship (SAR) study of the enzyme inhibitory and anticancer activity of 4-((4-(4-chlorophenyl … L Aurelio, CV Scullino, MR Pitman, A Sexton, V Oliver, L Davies, ... Journal of medicinal chemistry 59 (3), 965-984, 2016 | 71 | 2016 |
| Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity I Takizawa, MG Lawrence, P Balanathan, R Rebello, HB Pearson, E Garg, ... Oncotarget 6 (2), 604, 2015 | 60 | 2015 |
| Translational offsetting as a mode of estrogen receptor α‐dependent regulation of gene expression J Lorent, EP Kusnadi, V van Hoef, RJ Rebello, M Leibovitch, J Ristau, ... The EMBO journal 38 (23), e101323, 2019 | 35 | 2019 |
| PIM activity in tumours: A key node of therapy resistance RJ Rebello, AV Huglo, L Furic Advances in biological regulation 67, 163-169, 2018 | 27 | 2018 |
| CRISP3 expression drives prostate cancer invasion and progression M Volpert, L Furic, J Hu, AE O’Connor, RJ Rebello, S Keerthikumar, ... Endocrine-Related Cancer 27 (7), 415-430, 2020 | 26 | 2020 |
| A polygenic risk score predicts incident prostate cancer risk in older men but does not select for clinically significant disease A Bakshi, M Riaz, SG Orchard, PR Carr, AD Joshi, Y Cao, R Rebello, ... Cancers 13 (22), 5815, 2021 | 11 | 2021 |
| Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019; 11 MJ Watt, AK Clark, LA Selth, VR Haynes, N Lister, R Rebello | 8 | |
| Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med 11: eaau5758 MJ Watt, AK Clark, LA Selth, VR Haynes, N Lister, R Rebello, LH Porter, ... | 7 | 2019 |
| TP53 and Prognosis in mCRPC Survival: Biology or Coincidence? RJ Rebello, C Oing, S Gillessen, RG Bristow Clinical Cancer Research 25 (6), 1699-1701, 2019 | 4 | 2019 |
| A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease. Cancers [Internet]. 2021; 13 A Bakshi, M Riaz, SG Orchard, PR Carr, AD Joshi, Y Cao, R Rebello, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 1 | 2021 |
| Intermediate risk prostate cancer: disease heterogeneity linked to measurable biological features RJ Rebello, RG Bristow Clinical Oncology 32 (5), 298-302, 2020 | 1 | 2020 |